梅花生物(600873) - 2021 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders was ¥408,441,231.32, representing a 66.33% increase year-on-year[4]. - Operating revenue for the period was ¥5,308,348,754.19, reflecting a growth of 33.56% compared to the same period last year[4]. - Basic earnings per share increased to ¥0.13, up 62.50% from ¥0.08 in the previous year[4]. - The weighted average return on equity rose to 4.40%, an increase of 1.70 percentage points compared to the previous year[4]. - The net profit for the current period was ¥41,497.01 million, representing a significant increase of ¥16,639.59 million or 66.94% year-on-year, attributed to higher sales volumes and prices of key products[11]. - The total comprehensive income for Q1 2021 was CNY 414,970,065.30, compared to CNY 248,574,140.83 in Q1 2020, indicating a 67.0% increase[25]. - Net profit for Q1 2021 was ¥414,970,065.30, compared to ¥248,574,140.83 in Q1 2020, representing a 67.0% increase[24]. Revenue and Costs - The company's operating revenue for the current period reached ¥530,834.88 million, an increase of ¥133,378.43 million or 33.56% compared to the same period last year, driven by increased sales of flavor-enhancing products and amino acid products[11]. - Operating costs for Q1 2021 were ¥4,827,833,736.05, up from ¥3,709,461,775.44 in Q1 2020, reflecting a 30.2% increase[23]. - The total operating cost of CNY 3,525,370,911.12 for Q1 2021 was a 67.5% increase from CNY 2,101,633,847.67 in Q1 2020[26]. Cash Flow - The net cash flow from operating activities was -¥348,842,872.03, a decrease of 334.40% year-on-year[4]. - Cash flow from operating activities showed a net outflow of ¥34,884.29 million, a decrease of ¥49,766.82 million or 334.40% compared to the previous year, mainly due to increased prepayments for materials[13]. - Cash flow from operating activities for Q1 2021 was CNY -348,842,872.03, a decrease from CNY 148,825,306.42 in Q1 2020[29]. - The company experienced a net cash inflow from operating activities of CNY 4,784,972,577.49 in Q1 2021, compared to CNY 3,603,149,825.54 in Q1 2020[29]. Assets and Liabilities - Total assets at the end of the reporting period reached ¥19,278,566,251.66, an increase of 1.50% compared to the end of the previous year[4]. - Total current assets increased to CNY 6,139,450,872.11, up from CNY 5,551,767,321.73, representing a growth of approximately 10.6% year-over-year[16]. - Total liabilities decreased to CNY 9,532,196,573.77 from CNY 9,676,758,011.97, indicating a reduction of about 1.5%[17]. - The company's total equity increased to CNY 9,746,369,677.89 from CNY 9,316,550,020.73, showing a growth of approximately 4.6%[18]. - The company's total assets decreased from ¥14,645,131,654.37 in the previous year to ¥14,035,715,448.37 in Q1 2021[22]. - Total liabilities decreased from ¥7,892,216,178.79 to ¥6,974,088,371.08, indicating a reduction of approximately 11.6%[22]. Shareholder Information - The number of shareholders at the end of the reporting period was 115,539[7]. - The top shareholder, Meng Qingshan, held 27.55% of the shares, totaling 854,103,033 shares[7]. Investments and Financial Activities - The company reported a government subsidy of ¥16,815,447.93 related to its normal business operations[5]. - The company's investment activities resulted in a net cash outflow of ¥62,057.18 million, an increase of ¥43,596.14 million or 236.15% compared to the previous year, driven by increased investments in subsidiaries[13]. - The company incurred financial expenses of CNY 7,798,743.13 in Q1 2021, down from CNY 28,417,012.07 in Q1 2020, showing a decrease of 72.5%[26]. Inventory and Receivables - The accounts receivable increased by ¥21,159.82 million or 82.96% compared to the previous year, mainly due to increased revenue[10]. - The company's inventory stock decreased by ¥9,014.08 million or 34.18% compared to the previous year, as a result of the implementation of the employee stock ownership plan[10]. - Inventory increased to CNY 2,851,314,223.20, compared to CNY 2,222,502,469.41, reflecting a growth of approximately 28.3%[16]. Financial Stability - The company's financial expenses decreased by ¥4,166.73 million or 49.69% compared to the previous year, primarily due to lower interest expenses and reduced foreign exchange losses[11]. - The company's cash and cash equivalents decreased by ¥63,848.62 million or 40.62% compared to the end of the previous year, primarily due to increased prepayments and investments in financial products[9]. - The company reported a significant increase in other receivables to CNY 3,228,422,486.81 from CNY 3,479,587,575.30, a decrease of approximately 7.2%[19].